Axogen, Inc.: insider trades · United States · SEC (Form 4)

About Axogen, Inc.

Axogen, Inc. is a United States-based medtech company listed on the NASDAQ market (United States) and focused on peripheral nerve regeneration and repair. Rather than competing as a broad pharmaceutical player, Axogen operates in a specialized surgical niche: restoring peripheral nerve function after traumatic injury or surgical damage. The company was incorporated in Minnesota and is headquartered in Florida, with processing, warehousing, and distribution facilities in Ohio and Texas. Its geographic footprint is therefore largely U.S.-centric, and the company generates substantially all of its revenue from customers in the United States. ([ir.axogeninc.com](https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-25-000017/axgn-20241231.htm)) Axogen’s business model centers on the science, development, and commercialization of technologies used for peripheral nerve regeneration and repair. Its core product portfolio includes Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. These products address different steps in nerve surgery, from bridging nerve gaps to protecting repaired nerves and supporting soft tissue management. The company reports as a single operating segment, which underscores its highly focused strategy and its concentration on one clinical category rather than multiple end markets. ([ir.axogeninc.com](https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-25-000017/axgn-20241231.htm)) From a competitive perspective, Axogen is positioned as a category specialist in a market that remains relatively underpenetrated but increasingly validated by clinical and reimbursement progress. Its long-term opportunity depends on surgeon adoption, payer coverage, and continued clinical acceptance of peripheral nerve repair as a standard of care. In 2025, Axogen highlighted an expansion in commercial coverage and reimbursement for peripheral nerve repair using synthetic conduits and allografts, an important indicator of market development and a potential driver of future utilization. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/02/24/3243354/0/en/axogen-inc-reports-fourth-quarter-and-full-year-2025-financial-results.html)) Recent company milestones have been especially significant. In November 2024, the FDA accepted the filing of Axogen’s BLA for Avance® Nerve Graft and set a PDUFA goal date of September 5, 2025. On December 3, 2025, the FDA approved the BLA, marking a major regulatory inflection point for the company. In January 2026, Axogen completed an upsized public offering that generated $133.3 million in net proceeds; a portion of those funds was used to fully repay and terminate its Oberland loan facility, strengthening the balance sheet. For investors, Axogen represents a focused U.S. NASDAQ-listed healthcare story with a meaningful regulatory catalyst, a specialized product franchise, and a growing reimbursement backdrop. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/08/05/3127191/0/en/Axogen-Inc-Reports-Second-Quarter-2025-Financial-Results.html))